---
title: "The innovative drug sector is experiencing fluctuations and adjustments, while E Fund Hang Seng SCHK Innovative Drug ETF (159316) has seen net subscriptions against the trend"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282192239.md"
description: "On April 9th, despite the innovative drug sector experiencing fluctuations and weakness, the Hang Seng SCHK Innovative Drug Index fell by 1.1%, and the CSI Innovative Drugs Industry Index dropped by 1.3%. However, the E Fund Hang Seng SCHK Innovative Drug ETF (159316) saw a net subscription of 17 million shares against the trend. Guosen Securities pointed out that the government work report has listed biomedicine as an emerging pillar industry for the first time, which is expected to promote industrial innovation and support the development of biomedicine"
datetime: "2026-04-09T11:59:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282192239.md)
  - [en](https://longbridge.com/en/news/282192239.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282192239.md)
---

# The innovative drug sector is experiencing fluctuations and adjustments, while E Fund Hang Seng SCHK Innovative Drug ETF (159316) has seen net subscriptions against the trend

On April 9th, the innovative drug sector experienced fluctuations and weakened, opening lower and continuing to decline, with the Hang Seng SCHK Innovative Drug Index down 1.1% and the CSI Innovative Drugs Industry Index down 1.3%. In this market environment, the Hang Seng SCHK Innovative Drug ETF E Fund (159316, Connect Fund A/C: 024328/024329) achieved a net subscription of 17 million shares against the trend throughout the day.

According to Guosen Securities, the government work report has designated biomedicine as a new pillar industry for the first time and clearly stated that during the "14th Five-Year Plan" period, it will promote industrial innovation projects to help biomedicine become an important engine of new productivity. Currently, cooperation in innovative drugs is deepening, domestic R&D capabilities are being recognized by multinational pharmaceutical companies, BD transactions are rapidly increasing, and the commercialization prospects of the sector continue to improve.

For more details on the innovative drug-related ETFs under E Fund, see the image below:

Risk Warning: Funds carry risks, and investment should be cautious

### Related Stocks

- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159835.CN](https://longbridge.com/en/quote/159835.CN.md)
- [516080.CN](https://longbridge.com/en/quote/516080.CN.md)
- [560900.CN](https://longbridge.com/en/quote/560900.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)

## Related News & Research

- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Universal Digital Inc. Announces Termination of ETF Partnership Agreement | LFGMF Stock News](https://longbridge.com/en/news/286616540.md)
- [BNB ETF Could Be Next Big Crypto Breakthrough, Says Bloomberg Analyst](https://longbridge.com/en/news/286639724.md)
- [1 Rapidly Deteriorating ETF Screams That ‘Shop ‘Til You Drop’ Americans Have All But Keeled Over](https://longbridge.com/en/news/286429552.md)
- [VanEck, Grayscale file fresh BNB ETF amendments as race for next altcoin spot ETF accelerates](https://longbridge.com/en/news/286652991.md)